Chong Kun Dang Pharmaceutical Corp.

KSE 185750.KS

Chong Kun Dang Pharmaceutical Corp. Capital Expenditure for the year ending December 31, 2023: USD -52.84 M

Chong Kun Dang Pharmaceutical Corp. Capital Expenditure is USD -52.84 M for the year ending December 31, 2023, a -26.05% change year over year. Capital expenditure is cash spent on acquiring or maintaining fixed assets, such as property, plants, and equipment (PP&E).

Chong Kun Dang Pharmaceutical Corp. Capital Expenditure for the year ending December 31, 2022 was USD -41.92 M, a 3.39% change year over year.
Chong Kun Dang Pharmaceutical Corp. Capital Expenditure for the year ending December 31, 2021 was USD -43.39 M, a -28.39% change year over year.
Chong Kun Dang Pharmaceutical Corp. Capital Expenditure for the year ending December 31, 2020 was USD -33.80 M, a -57.71% change year over year.
Chong Kun Dang Pharmaceutical Corp. Capital Expenditure for the year ending December 31, 2019 was USD -21.43 M, a 2.71% change year over year.

Key data

Date	Capital Expenditure	Free Cash Flow	Depreciation And Amortization	Deferred Income Tax

KSE: 185750.KS

Chong Kun Dang Pharmaceutical Corp.

CEO	Mr. Young-Joo Kim
IPO Date	Dec. 6, 2013
Location	South Korea
Headquarters	8, Chungjeong-ro
Employees	2,286
Sector	Healthcare
Industries Pharmaceuticals Cosmetics Drugstores & Retail Pharmacies Personal Care

Description

Chong Kun Dang pharmaceutical Corp. engages in the manufacturing, marketing, and selling of medicines in South Korea and internationally. It provides prescription drugs for anti-hypertension, anti-hyperlipidemia, and anti-diabetics; over-the-counter drugs, such as Penzal, Prefemine, and Modcol, as well as consumer health products, such as insecticides, hair dye, etc.; and healthcare supplements with preventive benefits. The company also exports its products. Chong Kun Dang pharmaceutical Corp. was founded in 1941 and is headquartered in Seoul, South Korea.

Key trends

Past 5 years